High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia (vol 135, pg 866, 2020)

被引：0
|
作者：
Al-Sawaf, O.
Lilienweiss, E.
Bahlo, J.
机构：
来源：
BLOOD | 2022年 / 139卷 / 25期
关键词：
D O I：
10.1182/blood.2022015745
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3669 / 3669
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study
    Stilgenbauer, Stephan
    Ilhan, Osman
    Woszczyk, Darius
    Renner, Christoph
    Mikuskova, Eva
    Boettcher, Sebastian
    Tausch, Eugen
    Moore, Tom
    Tyson, Nicola
    Adamis, Helena
    Leblonde, Veronique
    Bosch, Francesc
    Foa, Robin
    BLOOD, 2015, 126 (23)
  • [22] Total cost of care with 12 months fixed duration of venetoclax plus obinutuzumab in previously-untreated chronic lymphocytic leukemia (CLL) patients
    Cho, Sang Kyu
    Manzoor, Beenish
    Sail, Kavita
    Ravelo, Arliene
    Shapouri, Sheila
    Sharmokh, Simon
    Kapustyan, Tatyana
    Johnson, Scott
    Parise, Helene
    Virabhak, Suchin
    Davids, Matthew
    LEUKEMIA & LYMPHOMA, 2020, 61 : 57 - 57
  • [23] The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
    Kreuzer, Karl-Anton
    Furman, Richard R.
    Stilgenbauer, Stephan
    Dubowy, Ronald L.
    Kim, Yeonhee
    Munugalavadla, Veerendra
    Lilienweiss, Esther
    Reinhardt, Hans Christian
    Cramer, Paula
    Eichhorst, Barbara
    Hillmen, Peter
    O'Brien, Susan M.
    Pettitt, Andrew R.
    Hallek, Michael
    LEUKEMIA, 2020, 34 (01) : 296 - 300
  • [24] The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
    Karl-Anton Kreuzer
    Richard R. Furman
    Stephan Stilgenbauer
    Ronald L. Dubowy
    Yeonhee Kim
    Veerendra Munugalavadla
    Esther Lilienweiss
    Hans Christian Reinhardt
    Paula Cramer
    Barbara Eichhorst
    Peter Hillmen
    Susan M. O’Brien
    Andrew R. Pettitt
    Michael Hallek
    Leukemia, 2020, 34 : 296 - 300
  • [25] Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
    Othman Al-Sawaf
    Can Zhang
    Hyun Yong Jin
    Sandra Robrecht
    Yoonha Choi
    Sandhya Balasubramanian
    Alex Kotak
    Yi Meng Chang
    Anna Maria Fink
    Eugen Tausch
    Christof Schneider
    Matthias Ritgen
    Karl-Anton Kreuzer
    Brenda Chyla
    Joseph N. Paulson
    Christian P. Pallasch
    Lukas P. Frenzel
    Martin Peifer
    Barbara Eichhorst
    Stephan Stilgenbauer
    Yanwen Jiang
    Michael Hallek
    Kirsten Fischer
    Nature Communications, 14
  • [26] Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
    Al-Sawaf, Othman
    Zhang, Can
    Jin, Hyun Yong
    Robrecht, Sandra
    Choi, Yoonha
    Balasubramanian, Sandhya
    Kotak, Alex
    Chang, Yi Meng
    Fink, Anna Maria
    Tausch, Eugen
    Schneider, Christof
    Ritgen, Matthias
    Kreuzer, Karl-Anton
    Chyla, Brenda
    Paulson, Joe
    Pallasch, Christian P.
    Frenzel, Lukas P.
    Peifer, Martin
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Jiang, Yanwen
    Hallek, Michael
    Fischer, Kirsten
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [27] Retrospective Comparison of Patients with Chronic Lymphocytic Leukemia Receiving BTK Inhibitors Versus Obinutuzumab/Venetoclax As Frontline Therapy
    Wang, Jiasheng
    Dasari, Srilatha
    Daunov, Michael
    Sekaran, Kanithra
    Kim, Yeseong
    Cooper, Brenda W.
    BLOOD, 2022, 140 : 9889 - 9890
  • [28] Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 10
  • [29] Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Blachly, James S.
    Rogers, Kerry A.
    Bhat, Seema A.
    Grever, Michael R.
    Kittai, Adam S.
    Jianfar, Mojgan
    Lozanski, Gerard
    Weiss, David M.
    Andersen, Barbara L.
    Patel, Priti
    Munugalavadla, Veerendra
    Butturini, Anna
    Xu, Yan
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2020, 136
  • [30] Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
    Woyach, Jennifer
    Ruppert, Amy S.
    Perez, Gabriela
    Booth, Allison M.
    Feldman, Diane
    Dib, Elie G.
    Jatoi, Aminah
    Le-Rademacher, Jennifer
    Heerema, Nyla A.
    Lozanski, Gerard
    Little, Richard
    Ding, Wei
    Hill, Brian T.
    Stone, Richard M.
    Mandrekar, Sumithra J.
    Byrd, John C.
    BLOOD, 2019, 134
12345